A model of the development of the brain as a construct of the thyroid system. by Howdeshell, Kembra L
In response to the mandate of the U.S.
Environmental Protection Agency (U.S.
EPA) to develop a set of screens and assays
to test chemicals for their possible estro-
genic or other endocrine effects, a workshop
was convened in June 1997 to assist the
U.S. EPA in developing tests available to
detect chemicals that might interfere with
the thyroid system. The “Workshop on
Screening Methods for Chemicals that
Interfere with Thyroid Hormone Action,
Function and Homeostasis” was convened
at the Nicholas School of the Environment,
Duke University, Durham, North Carolina
by the Chemical Manufacturers Association,
the U.S. EPA, and the World Wildlife Fund
(1). The workshop panelists agreed that
there were several assays currently in use in
the medical and toxicological communities
that could detect various mechanisms of
thyroid system disruption and suggested
using a combination of such tests to develop
an assay. They also pointed out that no
environmental contaminant had been iden-
tified as a thyroid hormone receptor (TR)
agonist or antagonist. They recommended
the use of thyroid histopathology and/or
quantiﬁcation of serum thyroid hormone to
reduce false positives and negatives, and sug-
gested that serum thyroid hormone concen-
trations could provide an initial screen in
mammals. Yet, despite the counsel of the
workshop participants, little progress has
been made toward the development of
assays to test chemicals for their impact on
the thyroid system. 
My purpose here is to expand upon the
results of the 1997 Durham workshop with
two main goals. The ﬁrst goal is to produce
an inventory of data on the development of
the thyroid system and concurrent develop-
ment of the brain to provide a visual aid for
the identification of thyroid-sensitive peri-
ods of brain maturation. The two visual
aids are designed in the form of timelines
based upon a literature review of scientific
journals and medical reference materials:
one timeline for human development from
conception to birth and a second timeline
for the laboratory rat from conception to
postnatal day (PND) 20, the comparable
developmental time period relative to
humans. The second goal is to discuss what
is known about how man-made chemicals
can interfere with the normal production,
transport, metabolism, and excretion of
thyroid hormone during development, and
their known impact on the thyroid system
during development. Perturbation of the
interaction of the thyroid and retinoic acid
(RA) systems is also briefly reviewed.
Finally, thyroid hormone sensitivity of the
nervous system derivative of the inner ear,
the cochlea, is discussed as a potential end
point of thyroid hormone disruption.
The literature review presented below
indicates that thyroid hormone is poten-
tially important from the very earliest
stages of development—from the mature
oocyte and throughout gestation. Thyroid
receptors, the proteins necessary for thyroid
hormone signal transduction, have also
been detected during these periods, and
there is evidence of structural and func-
tional defects in brain development when
thyroid hormone is absent or in short sup-
ply. The timing of the onset of fetal thy-
roid function and the acquisition of
regulatory mechanisms controlling thyroid
hormone action in the fetal brain indicate
that thyroid hormone of maternal origin
plays an important role in early develop-
mental events in the brain. Thus, by super-
imposing the timing of brain development
onto development of the thyroid system, it
becomes clear that any environmental
chemical that affects maternal thyroid sta-
tus or that directly affects thyroid hormone
action may exert very speciﬁc effects on the
complex mechanisms underlying normal
brain development.
Developing a Timeline Model
of Thyroid System and Brain
Development
Human Thyroid System
Development
The timeline begins with a review of the
basic development of the thyroid system
from conception until birth in humans
(Figure 1).
Thyroid gland development. Develop-
ment of the human thyroid gland begins
in the third week of gestation (2) (Figure
1, grid 1). On gestation day (GD) 16–17,
the embryonic thyroid is visible as an out-
growth in the floor of the primitive buccal
cavity (the site of the future pharynx).
Additional lateral contributions to the
embryonic thyroid originate from a por-
tion of the fourth pharyngeal pouches;
these lateral contributions are the origin
of the C-cells, which produce calcitonin.
The thyroid gland tissues merge and
migrate to their final location by
GD45–50. By GD70, the thyroid gland is
well developed; it begins concentrating
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Thyroid hormone is essential for normal brain development. However, little is known about the
molecular and cellular mechanisms that mediate thyroid hormone action on the developing brain
or the developmental events selectively affected. Consequently, although a large number of envi-
ronmental chemicals interfere with the thyroid system, there are few neurodevelopmental end
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about the relative timing of normal brain construction and thyroid system development, with spe-
cial focus on the period of in utero development in humans and the comparable developmental
period in laboratory rats. These data are presented as a timeline to aid in the identification of
thyroid-sensitive end points in brain development and to highlight important data gaps. I discuss
the known influence of certain synthetic chemicals on the thyroid system and include a brief
review of the effects of developmental exposure to chemicals on thyroid system function. The
relationship between the thyroid hormone and retinoic acid systems, as well as the thyroid hor-
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http://ehpnet1.niehs.nih.gov/docs/2002/suppl-3/337-348howdeshell/abstract.htmliodide and producing thyroid hormone at
this time (3). Thyroglobulin (TBG), the
precursor protein upon which thyroid
hormone is produced and stored, is pre-
sent as early as GD29 in thyroid follicle
cells (2). As the thyroid follicle cells
mature, TBG levels are detected in fetal
serum by gestation week 11 and increase
through gestation (4). 
Maternal/fetal thyroid hormone.
Thyroid hormone is produced from iodi-
nated tyrosine residues to form 3,5,3´,5´-
tetraiodothyronine (thyroxine [T4]) and
3,5,3´-triiodo-L-thyronine (T3). T4 is the
most abundant product of the thyroid
gland in circulation and is peripherally
deiodinated to T3, the bioactive form of
thyroid hormone. The bioavailability of
thyroid hormone is tightly controlled by
the binding of the hormone to serum-bind-
ing proteins (i.e., TBG, transthyretin, and
albumin), which maintains a ﬁxed percent-
age of free (not bound to serum-binding
protein) thyroid hormone available to elicit
thyroid action (5). During pregnancy,
there is increased peripheral metabolism of
free thyroid hormone; the pool of serum
protein-bound thyroid hormone also
increases during this time to maintain the
proper level of free hormone (6). Thus, the
total (free and bound-to-serum protein)
levels of maternal T4 and T3 increase dur-
ing pregnancy to meet increased demand,
while the maternal level of free T4 remains
constant (7,8) (Figure 1, grid 1). 
It had long been thought that fetal
exposure to maternal thyroid hormone was
nonexistent or limited, because maternal
T4 is largely converted to reverse T3 (an
inactive form) in the placenta (8).
However, in 1989, Vulsma et al. (9),
demonstrated that maternal T4 did reach
the fetus by observing infants with either
thyroid agenesis or a total organification
defect, a mutation abolishing the ability to
iodinate thyroid protein. In infants with
these conditions, the maternal circulation
provides 35–70 nmol/L of serum T4
(20–44% of the normal levels) as measured
within the first 4 weeks of postnatal life;
normal serum T4 levels during this time
period are 80–170 nmol/L serum T4.
Maternal–embryo transfer of thyroid hor-
mones has been detected in embryonic
coelomic fluid (total T4 = 961 ± 193
pmol/L or 747 ± 150 pg/mL; total T3 = 33
± 13 pmol/L or 18.5 ± 7.3 pg/mL) and
amniotic fluid (20 ± 5 pmol/L or 16.0 ±
3.8 pg/mL; total T3 was below the detec-
tion limit of the assay) at 5 to 11 weeks of
gestation (7). At term, total and free serum
levels of fetal T4 are similar to maternal val-
ues, whereas maternal serum T3 levels
(total and free) continue to be two to three
times greater than fetal free T3 levels (4).
Recent studies indicate that the maternal
contribution of thyroid hormone is critical
for proper in utero brain development, as
evidenced by impaired psychomotor devel-
opment and visuospatial processing in off-
spring born to mothers with low serum
levels of free T4 (10–13).
As mentioned above, fetal thyroid hor-
mone production begins at approximately
10 weeks of gestation in in vitro organ cul-
ture of human thyroid tissue (3) (Figure 1,
grid 1). In an in vivo study, Bernal and
Pekonen (14) detected T3, but not T4, in
homogenized human brain tissue at 10 and
12 weeks of gestation. The tissue concentra-
tion of free T3 is consistently higher in the
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Figure 1. Timeline of human thyroid system and brain development from conception to birth. Estimation of neurogenesis adapted from Bayer et al. (49).nuclear cell fraction than in the cytoplasmic
fraction of 10–13 gestational week human
brains, thus providing evidence for a gradi-
ent of increased free T3 concentration in
the cell nuclei versus the cytosol (15); a sim-
ilar free T3 concentration gradient from
plasma to cytosol to nuclei has been
reported in the adult rat brain (16).
Brain tissue levels of T4 exceed T3
levels at 16 weeks of gestation and beyond
(14). Thorpe-Beeston et al. (4) reported
increasing levels of free T4 and T3 in cord
blood from gestation weeks 12–40.
Increased thyroid hormone production is
due, in part, to an increase in thyroid gland
follicular cell uptake of iodide from gesta-
tion weeks 18–20 and subsequent matura-
tion of the hypothalamic-pituitary–thyroid
axis (see below). The autoregulation of
iodide by the fetal thyroid gland develops
during 36–40 weeks of gestation (17). 
Thyroid hormone receptors. Thyroid
hormone elicits its effect via binding to the
TR, a nuclear transcription factor (18).
The ligand-bound thyroid receptor dimer-
izes with a second TR and binds to a thy-
roid response element on the DNA to elicit
gene expression. Thyroid hormone recep-
tors are products of two genes: c-erbAα
encoding the isoforms TRα1 and TRα2,
and c-erbAβ encoding the isoforms TRβ1
and TRβ2. All TR isoforms bind both T4
and T3, with the exception of TRα2;
TRα2 does not bind hormone due to a
mutation in its ligand-binding domain.
The abundance of TR isoforms is thought
to allow for the tissue speciﬁcity of thyroid
hormone action. Additionally, the TR can
bind with the retinoic X receptor (RXR) of
the RA system, which will be described
later in this article.
Thyroid hormone receptors appear
before the initiation of fetal thyroid func-
tion, and they increase in association with
the increase in fetal thyroid hormone pro-
duction (Figure 1, grid 1). Bernal and
Pekonen (14) identified TR protein in
human fetal brain tissue at 10 weeks of ges-
tation. More recently, the expression of
TRα1 and TRβ1 mRNA was detected in
human whole-brain samples as early as 8
weeks of gestation (19). TRα1 mRNA
increased 8-fold from 8 through 13.0
weeks of gestation, whereas expression of
TRβ1 mRNA increased at 13.9 weeks of
gestation after low-level expression from 8
to 10 weeks of gestation. Similarly, Kilby et
al. (20) detected the expression of all TR
isoforms (TRα1, TRα2, TRβ1, TRβ2) in
cerebral cortex samples from 10 to 16
weeks of gestation. In fetal cerebral cortex
and cerebellum, only TRα1 and TRα2
protein was detected in the first trimester
samples (11–13 weeks of gestation), while
receptor protein of all four TR isoforms
was detected in the second (15–25 weeks
of gestation) and third trimester (26–40
weeks of gestation) samples (20). TR
mRNA and protein have been detected in
the human brain at the earliest time points
studied, which suggests that TR may be
present even earlier in brain development.
Interestingly, the mRNA of all four TR
isoforms are expressed in mature human
oocytes and granulosa and cumulus cells
(21), thus indicating that thyroid hormone
may influence development from the time
of conception and early embryogenesis.
Human Hypothalamic–Pituitary–
Thyroid Axis Development
Thyroid hormone production is regulated
by a sensitive feedback system between the
hypothalamus, pituitary, and thyroid
gland. Thyrotropin-releasing hormone
(TRH) is secreted from the hypothalamus,
which acts upon the pituitary to stimulate
the release of thyrotropin (also called thy-
roid-stimulating hormone [TSH]). TSH
then acts upon the thyroid gland to initiate
thyroid hormone production. Increased
circulatory levels of thyroid hormone then
provide negative feedback on the hypothal-
amus and pituitary to inhibit T4 and T3
production, thus maintaining proper levels
of hormone availability.
Pituitary gland development. Although
the neuroendocrine control of thyroid hor-
mone function develops much later in fetal
development, the pituitary and hypothala-
mic structures begin to develop within
weeks of thyroid gland emergence (22,23).
The anterior pituitary gland is derived from
Rathke’s pouch, which ﬁrst appears on ges-
tation week 4 as an outgrowth of the primi-
tive buccal cavity (Figure 1, grid 2). By
gestation week 5, the anterior pituitary is
connected to a derivative of the cerebrum
that will become the posterior pituitary. Cell
differentiation in the pituitary is initiated by
7–8 weeks of gestation. Basophils, which
include thyrotropes (thyrotropin-secreting
cells) and gonadotropes (gonadotropin-
secreting cells), are detected in the pituitary
by 8 weeks of gestation (22), and large num-
bers of thyrotropes are present by 12–13
weeks of gestation (23). The development of
the hypophyseal portal system, the vascula-
ture connecting the pituitary to the median
eminence, is concurrent with pituitary gland
development; capillaries of the hypophyseal
portal system have been detected as early as
7–8 weeks of gestation. 
Thyroid-stimulating hormone. TSH is
ﬁrst detected in the fetal human pituitary by
10–12 weeks of gestation (22) (Figure 1,
grid 2). Fetal pituitary TSH levels are rela-
tively low until gestation weeks 16–20, after
which they increase to parturition. Fetal
serum levels of TSH are first observed at
10–12 weeks of gestation. Fetal serum levels
reach peak concentrations around gestation
weeks 22–30, then decrease slightly until
birth (22,23). The decrease in TSH before
birth is thought to be, in part, in response to
the onset of the negative feedback system of
the maturing hypothalamic–pituitary–
thyroid system. 
Hypothalamus development. The hypo-
thalamus develops from the ventral portion
of the diencephalon and is visible by 5
weeks of gestation (22,23) (Figure 1, grid
2). Hypothalamic nuclei and the fibers of
the supraoptic tract are detectable at 12–14
weeks of gestation. The hypothalamic
nuclei and their processes continue to
mature through 30–35 weeks of gestation.
The hypothalamo–hypophyseal portal sys-
tem, the vasculature connecting the hypo-
thalamus with the pituitary via the median
eminence, is observed in human fetuses as
early as 11.5 weeks of gestation (24). This
circulatory system, also referred to as the
primary portal system, continues to mature
through late gestation. 
Thyrotropin-releasing hormone. TRH is
detected in fetal whole-brain samples by 4.5
weeks of gestation (25). The levels of TRH
detected this early are likely of maternal ori-
gin, as the fetal hypothalamus is just begin-
ning to develop and maternal TRH is able
to cross the placental barrier (2). TRH is
detected in fetal hypothalamus extracts as
early as 8–11 weeks of gestation (25,26).
The hypothalamic–pituitary–thyroid axis
begins to mature during the second half of
gestation (22). The fetal pituitary can
respond to TRH as early as 25 weeks of ges-
tation; this is evidenced by an increase in
fetal TSH secretion upon maternal admin-
istration of TRH, as measured by a cordo-
centesis procedure on normal pregnancies
during 25–37 weeks of gestation (4).
Rat Thyroid System Development
Thyroid gland. The developing rat thyroid
gland is ﬁrst visible on GD9 as an endoder-
mal thickening in the primitive buccal cav-
ity (27) (Figure 2, grid 1). The thyroid
gland is well developed and positioned in
the fetal thyroid gland contains TBG and is
capable of concentrating iodide. In vitro
cultures of rat thyroid indicate its ability to
synthesize thyroid hormone at least as early
as GD20 (3).
Maternal and fetal/neonatal thyroid
hormone. Maternal transfer of thyroid
hormone to the embryo/fetus has been
verified in the laboratory rat (Figure 2,
grid 1). Thyroid hormone is detected in
rat embryotrophoblasts as early as GD9
(total T4 = 4.46 ± 1.04 ng/100 mg and
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Woods et al. (29) reported that rat embry-
otrophoblasts (GD9–10) contained 21%
of the T4 and 54% of the T3 of the mater-
nal dose of radiolabeled T4 or T3 1 hr after
administration. Versloot et al. (30)
demonstrated that even marginal maternal
iodide deficiency decreases the availability
of T4 for the fetus in the rat. Normal
maternal serum T4 levels are essential to
the maintenance of fetal serum T4 avail-
able for local conversion to T3 (31). 
The total T4 and T3 concentrations in
rat fetuses increase dramatically from
GD18 until birth because of maturation of
hormone synthesis of the fetal thyroid
gland (22,32) (Figure 2, grid 1). Total T4
and T3 tissue levels of GD18 rat fetuses
measured 190 ± 38 pg/g and 33 ± 4 pg/g,
respectively (28). By GD21, fetal plasma
levels had reached 0.4 ± 0.03 µg/dL total
T4 and 17 ± 4 ng/dL total T3. After birth,
neonatal serum levels of total T4 rise dra-
matically from 1.0 µg/dL at PND5 to a
peak level of 6 µg/dL at PND17 (33).
Neonatal serum levels of total T3 rise in
parallel to total T4 with a peak serum value
of 108 ng/dL reached on PND28. Free
serum T4 and T3 levels follow a pattern
similar to the total serum values (22). The
serum levels of T4 and T3 reach adult val-
ues at approximately PND40.
Fetal/neonatal thyroid hormone receptors.
Fetal TRs are present early in fetal rat brain
development (34). TRβ1 and TRβ2 isoforms
were detected as early as GD12.5 in the rat
otic vesicle in the fetal brain, the portion of
the embryonic inner ear that develops into
the cochlea (35) (Figure 2, grid 1). Falcone et
al. (36) detected TRα1, TRα2, and TRβ1
protein at GD14 in rat brains, particularly in
regions of neuronal and glial cell nuclei.
Levels of TR in the fetal brain increase 3-fold
from GD14 to GD16–17, then remain
steady until birth (34). Following birth, TR
mRNA and protein levels increase through
the second week of postnatal life, reaching
peak mRNA concentrations on PND10 and
protein concentrations on PND15 (37,38). 
There is evidence that the TRα and
TRβ isoforms are selectively expressed in
different brain regions during development
and may therefore mediate different
functions. For example, Bradley et al. (39)
found that the TRβ1 mRNA is selectively
expressed in the ventricular zone of the
early cortex where cells undergo prolifera-
tion and early fate specification. However,
as these cells leave the cell cycle and begin
to differentiate, they migrate away from the
ventricular zone, cease expressing TRβ1,
and begin expressing TRα1. Likewise,
Strait et al. (40) observed a selective pattern
of TRβ1 and TRα2 expression in cerebel-
lar sections of neonatal (PND4) and adult
(PND60) rats. TRβ1 protein was strongly
localized to the nuclei of Purkinje cells and
weakly present in the nuclei of granule
cells, whereas TRα2 was detected only in
the nuclei of granule cells. Neither TR iso-
form was detected in the neuronal axons or
glial cells. In contrast, Leonard et al. (41)
concluded that TRα2 is selectively
expressed in astrocytes, but not neuronal
cells. Although studies using transgenic
mice and targeted deletion/mutations have
helped elucidate some of the physiological
functions of specific TR isoforms (42),
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Figure 2. Timeline of rat thyroid system and brain development from conception to PND20. Conception = GD0 and birth = PND1. Timing of neurogenesis adapted
from Bayer et al. (49).distinct roles for the TR isoforms in
specific neurodevelopmental events have
yet to be identiﬁed. 
Rat Hypothalamus–Pituitary–
Thyroid Axis Development
Pituitary development. The ﬁrst sign of rat
anterior pituitary development is the for-
mation of Rathke’s pouch, which appears
on GD9.5 (27) (Figure 2, grid 2). By
GD16, the pituitary is well developed and
secretory granules are present (22). The
number of granule cells increases from
GD18 through the end of the first post-
natal week. The posterior pituitary is well
developed by GD18. The pituitary portal
system develops in concert with the pitu-
itary gland and is well developed by GD17.
Thyroid-stimulating hormone. Pituitary
TSH mRNA expression begins on GD15
(43), while TSH protein levels are first
reported at GD17 measuring 24.8 ± 2
ng/pituitary (44) (Figure 2, grid 2). Fetal
pituitary levels climb to 162.0 ± 9.64
µg/pituitary for males and 194.5 ± 9.14
µg/pituitary for females. Serum levels of
TSH are 20 ng/100 µL at birth and
increase to maximum postnatal serum lev-
els by PND7–8 (40 ng/100 µL TSH) (22).
Pituitary levels of TSH increase from 170
ng/µg protein at birth to approximately 1
µg/µg protein by PND10–12. The levels of
pituitary and serum TSH slowly decrease
from PND14–16 until reaching adult lev-
els at PND40 (33).
Hypothalamus development. The
developing hypothalamus is ﬁrst visible on
GD12.5 as the diencephalon differentiates
into the hypothalamus, epithalamus
(which comprises the pineal gland), and
the thalamus (27) (Figure 2, grid 2). By
GD14–15, hypothalamic nuclei are pre-
sent and there is continued ingrowth of
axons into the median eminence (22). The
hypothalamus and median eminence are
nearly morphologically complete by the
third postnatal week. The vasculature of
the hypothalamo–hypophyseal portal sys-
tem is known to reach the median emi-
nence late in the ﬁrst postnatal week, with
continued development of the portal system
occurring through postnatal weeks 5–6. 
Thyrotropin-releasing hormone. TRH
mRNA can be detected as early as GD14 in
neurons of the rat fetal hypothalamus (45).
By GD15, TRH mRNA is detected in the
developing paraventricular nuclei of the
hypothalamus. At birth, TRH mRNA was
detected in all areas of the brain known to
express it in adulthood. Adult TRH mRNA
expression patterns are present by PND22.
TRH is produced in low levels (6.0 ± 0.5
pg/mg) in the rat hypothalamus as early as
GD16 and increases approximately 3-fold
by GD20 (46). TRH levels increase to
adult levels by PND17–29, then decrease
transiently between PND31–41; adult lev-
els are once again reached at PND50
(33,44). Although TRH is present in the
hypothalamus in late gestation, it does not
appear to influence the hypothalamic–
pituitary–thyroid axis until the second week
of postnatal life (22,47). 
Mammalian Brain Development
(Human and Rat)
Central nervous system embryogenesis
begins with formation of the neural tube.
This process begins around 2 weeks of ges-
tation in humans (GD8–9 in rats), with
the neural plate developing from ectoderm
as directed by the notochord (27,48)
(Figure 1, grid 3 human; Figure 2, grid 3
rat). As the neural plate invaginates and
begins to fuse, neural crest cells are derived
from the ectoderm at the interface closing
neural tube and skin ectoderm. The neural
crest cells are progenitors of several compo-
nents of the nervous system, including the
sensory ganglia of the spinal and cranial
nerves, the Schwann cells (neuroglial cells
covering the peripheral nerves), the
meninges (connective tissue covering of the
brain), and other derivatives. The neural
tube closes in a caudal to rostral pattern
with hindbrain (rhomencephalon) regions
forming before forebrain (telencephalon)
regions. In humans, the neural tube forma-
tion begins at approximately GD18 (rats
~GD9–9.5) and is complete by GD26–28
(rats GD10.5–11) (48).
Bayer et al. (49) estimated the timing
of human fetal brain neurogenesis based
upon extensive histological observation of
rat fetal and neonatal brain development
compared with anatomical drawings and
photographs of human fetal brain develop-
ment. The initiation of neurogenesis in the
developing brain proceeds in a caudal to
rostral direction beginning with the spinal
cord and the hindbrain derivatives, includ-
ing the myelencephalon (medulla) and
metencephalon (pons and cerebellum)
(Figure 1, grid 3 human; Figure 2, grid 3
rat). Neurogenesis subsequently begins in
the mesencephalon (tectum and tegmen-
tum) and diencephalon (thalamus and
hypothalamus) (Figure 1, grid 4 human;
Figure 2, grid 4 rat). The telencephalon is
the last of the brain regions to begin to
develop; it encompasses the cerebral struc-
tures, including the basal ganglia (striatum
and pallidum), amygdala, and cerebral cor-
tex (neocortex, limbic and piriform cor-
tices, hippocampal regions, and the
olfactory bulb) (Figure 1, grid 5 human;
Figure 2, grid 5 rat). Neurogenesis in the
cerebellum, hippocampus dentate granule
cells, and the olfactory bulb continue into
postnatal life in humans and rats (49).
Recent studies in rodents and primates sug-
gest that regions of the hippocampus and
olfactory bulb continue to undergo neuro-
genesis well into adulthood (50,51).
The initiation of migration of neurons
is concurrent with the period of neurogen-
esis and is usually completed within days in
the rat and within weeks in humans (49).
Differentiation is a process that generally
begins after a brief pause following migra-
tion (49); however, cell fate determination
may begin as early as migration (48). In
humans, synaptogenesis is reported to
begin as early as gestation month 2 and
continues into postnatal life, with a peak in
the ﬁrst year of life (52) (Figure 1, grid 6).
In rats, synapse formation is detected as
early as GD18 in the substantia nigra (53),
with the majority of synapse formation
occurring after birth (54,55) (Figure 2, grid
6). Myelin production ﬁrst appears around
gestation month 5 in humans and contin-
ues well into postnatal life (52) (Figure 1,
grid 6). Myelin protein mRNA is clearly
expressed in cranial nerve VIII (56) by
PND2, and in the cerebellum and mesen-
cephalon by PND10, followed by expres-
sion in more rostral brain regions later in
rat development (57) (Figure 2, grid 6). 
Thyroid Hormone Inﬂuence 
on Brain Development
Thyroid hormone is essential for brain
development (37, 58–62); the following
section is a brief summary of some of thy-
roid hormones’ effects on neuronal prolif-
eration, migration, synaptogenesis and
myelination. For example, in the cerebel-
lum, thyroid hormone plays an important
role in granule cell proliferation and sur-
vival. Granule cell proliferation, as mea-
sured by 3H-thymidine, is enhanced by
thyroid hormone and suppressed by
hypothyroidism (63). In addition, granule
cell apoptosis, as measured by terminal
deoxynucleotydl transferase-mediated
dUTP nick end-labeling, was increased 8-
fold in hypothyroid animals (64). Direct
effects of thyroid hormone on the expres-
sion of genes encoding growth factors and
antiapoptotic genes may mediate these
effects. Neveu and Arenas (65) found that
hypothyroidism increased the abundance
of mRNAs encoding nerve growth factor
and neurotrophin 4/5 and severely reduced
the expression of the mRNAs encoding
neurotrophin 3 and brain-derived neu-
rotrophic factor in the cerebellum.
However, there were no effects of thyroid
hormone on levels of the full-length tyro-
sine kinase B and C receptor mRNAs. In
addition, Muller et al. (66) found that
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administration prevented the increased
apoptosis in the cerebellum induced by
hypothyroidism. 
Thyroid hormone availability influ-
ences neuronal migration, as evidenced by
decreased whole-brain weight and densely
packed neurons in the hypothyroid rat
cerebellum (63,67). Many genes involved
in the process of neuronal migration are
sensitive to thyroid hormone (62). For
example, Alvarez-Dolado et al. (68)
reported that thyroid hormone increases
mRNA expression and translation of reelin,
which encodes a large extracellular protein.
Conversely, hypothyroid conditions signiﬁ-
cantly reduce the abundance of reelin-con-
taining cells and the intensity of signal
from each cell. Neural migration is also
influenced by thyroid hormone effects on
astrocytes, a glial cell type. Astrocytes
secrete laminin, a key guidance signal for
the migration of neurons (69). In the
developing rat cerebellum, thyroid hor-
mone deficiency delays the expression of
laminin, and total laminin concentration is
35% less intense than in controls (70). 
Synaptogenesis is negatively affected in
the hypothyroid brain due to the decrease
in axonal length and branching of neurons,
thus reducing neuronal connections.
Hypothyroidism decreases neural axonal
density and growth in the cerebral cortex
(71) and reduces the dendrite branching of
Purkinje cells in the cerebellum (72), pyra-
midal cells in the cerebral cortex (73), and
cortical neurons of the corpus callosum
(74). Rami and Rabie (75) report a delay in
hippocampal synaptogenesis under
hypothyroid conditions, based on measure-
ments of synaptophysin, a marker protein
of mature synaptic vesicles. In the cerebel-
lum, mature granule cells in the internal
granular layer express a synaptotagmin-
related gene 1 (Srg1) (76). Thyroid hor-
mone upregulates Srg1 mRNA, whereas
hypothyroidism decreases its expression.
Finally, a reduction in myelination is also a
common phenotype of the hypothyroid
neonatal brain. The decrease in myelina-
tion is due, in part, to the decrease in
length and branching of neural outgrowths
as previously described. Thyroid hormone
also influences myelination by stimulating
the differentiation of oligodendrocytes,
which are the glial cells responsible for the
production of the myelin proteins (77).
Ibarrola and Rodríguez-Peña (57) report
that hypothyroidism causes delayed expres-
sion of four major myelin protein genes:
myelin basic protein (MBP), proteolipid
protein (PLP), 2´:3´-cyclic nucleotide 3´-
phosphodiesterase, and myelin-associated
glycoprotein; the delayed expression of
such genes leads to an overall decrease in
myelin protein production. In contrast,
hyperthyroidism increases the MBP and
PLP mRNA, and this effect is likely due to
an increased abundance of mature oligo-
dendrocytes (77).
Gliogenesis and its responsiveness to
thyroid hormone has most often focused
on the development and maturation of the
astrocytes and oligodendrocytes, which
develop well after the bulk of neurogenesis
is complete (48,77). However, radial glial
and microglial cells are present much ear-
lier in brain development and are also
influenced by thyroid hormone. Radial
cells provide a framework for neuronal
migration (78,79) and are the precursor
cell line to astroglial cells (80). In mice,
radial glial cells are present in the develop-
ing neural tube as early as GD9.5 (81) and
by estimated GD11 in rats (27).
Microglial cells are macrophage cells,
which phagocytize dead cells and cellular
debris following apoptosis during brain
development. In mice, microglia progeni-
tor cells are derived from the yolk sac and
are present in future brain tissue by GD8
and mature microglial are detected by
GD13 (82); in rat the estimated time
points are GD9.5 and GD14, respectively
(27) (Figure 2, grid 6). Radial and
microglia are also present very early in
human gestation (52,83) (Figure 1, grid 6).
Prenatal hypothyroidism inhibits the matu-
ration of radial glial cells in the CA1 region
of GD21 rat hippocampus, as measured by
the abundance of glial ﬁbrillary acidic pro-
tein (GFAP) (84). A deficiency of GFAP
during development inhibits the branching
necessary for astrocyte–neuronal connec-
tions and decreases the long-term potentia-
tion capacity, a factor essential to learning
and memory (85). Microglial cells express
the TRα1 and TRβ1 isoforms and are
influenced by thyroid hormone (86).
Microglial cell density and process forma-
tion are depressed in the parietal cortex of
neonatal rats exposed to hypothyroid condi-
tions from GD16 through lactation (86). In
contrast, hyperthyroidism induced by T3
injections to euthyroid and prenatally
hypothyroid rat pups increased microglial
cell survival and branching of the develop-
ing axonal fiber tracts of the corpus callo-
sum. Although Lima et al. (86) identify the
ﬁrst postnatal week in rats as a critical win-
dow for thyroid hormone influence, they
suggest that maternal thyroid hormone
could be inﬂuencing the early development
of fetal microglial cells. The fact that both
radial glial and microglial cells are nega-
tively affected by hypothyroid conditions
indicates that thyroid hormone may influ-
ence very early stages of brain development. 
The complexity of development within
each brain region suggests that investiga-
tions of thyroid hormone inﬂuence on the
brain should be conducted with as much
speciﬁcity to region as possible. For exam-
ple, different cell populations within each
area of the brain often have their own
unique timeline for birth and maturation
(49,52). Neurogenesis of the Purkinje and
granule cells populations occurs at different
times in the cerebellum; Purkinje cells
emerge between GD13–15 in the rat
(human gestation weeks 5.3–7.0), whereas
the granule cells do not begin to appear
until PND4 in the rat (human gestation
week 24.0) (49). Similarly, the peak prolif-
eration of granule cells in the hippocampus
occurs after birth, whereas maximal neuro-
genesis of the hippocampal CA3 neurons
occurs between GD17 and GD20 (49).
Different regions of the brain also have
particular developmental schedules. As
demonstrated in Figures 1 and 2, neuroge-
nesis is initiated in hindbrain derivatives
(i.e., medulla and pons) well before it
begins in forebrain derivatives (i.e., neocor-
tex and hippocampus) in both humans and
rats (49). Similarly, Herschkowitz et al.
(52) reviewed the timing of brain develop-
ment in humans and found the onset of
myelination occurred at specific times for
the various brain areas. For example, myeli-
nation of the spinal nerve roots begins
around gestation month 5, whereas myeli-
nation of the auditory cortex does not
begin until gestation week 9. Likewise,
myelinogenesis in the rat brain occurs in a
regional pattern (87). Myelination of the
vestibulo–cochlear nerve (cranial nerve
VIII) is evident by PND2 (56), whereas
onset of myelin protein gene expression in
the cerebellum and cerebral cortex occurs
on PND10 and PND20, respectively (57). 
Interaction of Retinoic Acid and
Thyroid Systems during Brain
Development
The interaction of the vitamin A and thy-
roid systems is important for eliciting thy-
roid hormone action (88). Vitamin A
(retinol) is obtained from the diet and
passes through two enzymatic conversions
to derive the bioactive metabolite RA. Like
TR, RA receptors are members of the
steroid/retinol/vitamin D/thyroid hormone
nuclear receptor superfamily. There are
two classes of RA receptors: the retinoic
acid receptor (RAR), which binds most
naturally occurring RAs, and RXR, which
binds only 9-cis-RA. These RA receptor
isoforms elicit RA action by binding as
homodimers or heterodimers with each
other. Thyroid receptors can heterodimer-
ize with both classes of RA receptors (18).
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with the RXR, which often results in more
effective activation of the corresponding
thyroid or RA response element than a TR
or RXR homodimer (88). In the rat, TSHβ
gene expression is regulated by T3 and RA
via TR-RXR and RAR-RXR heterodimers,
respectively (89). In vitro studies of rat optic
nerve oligodendrocyte precursor cells deter-
mined that RA as well as thyroid hormone
plays a role in promoting the differentiation
of these cells into mature oligodendrocytes
cultures, possibly through inﬂuence on the
activity of transcription factor activator pro-
tein 1 (90). Koibuchi and Chin (91)
reported that thyroid hormone accelerated
the initiation of RA orphan receptor α
expression in developing rat Purkinje cells
in the hypothyroid rat cerebellum, suggest-
ing that thyroid hormone may contribute
to the Purkinje cell differentiation via inter-
action with the RA system. 
Xenobiotic Interference with
the Thyroid System
As mentioned in my introduction, the pan-
elists at the Duke University workshop
agreed that there were assays currently in
use that could detect changes in thyroid
hormone action and gland function (1).
They identified a number of assays that
could be used to screen chemicals for their
potential to interfere with the thyroid sys-
tem but emphasized that none of the assays
were adequate as a first-tier screen. The
assays were as follows: a) a TRH challenge,
which tests the integrity of the hypothala-
mic–pituitary–thyroid axis by measuring
TSH production following the administra-
tion of TRH; b) the use of a perchlorate
discharge test to detect chemicals that
inhibit the uptake of iodide by the thyroid
gland; c) a quantiﬁcation of thyroid peroxi-
dase, the key enzyme in thyroid hormone
production that assures the oxidation of
iodide, the incorporation of iodide into the
tyrosine residues on TBG, and the coupling
of the di- and triiodotyrosyl residues on
TBG to form thyroid hormone; d) a series
of thyroid hormone competitive binding
assays to quantify maternal serum-binding
proteins, which can predict changes in fetal
thyroid hormone concentrations; e) a mea-
sure of iodothyronine deiodinase activity of
the three tissue speciﬁc enzymes (type I, II,
III proteins) that facilitate the removal of
iodine from thyroid hormone; and f) a
measure of the rate of thyroid hormone glu-
curonidation using an in vivo exposure par-
adigm followed by ex vivo examination
using hepatic microsomes. Glucuronidation
of thyroid hormone, which is facilitated by
the enzyme uridine diphosphate-glucuronyl
transferase (UDP-GT), produces an
inactive, excretable form of the hormone;
under normal conditions, glucuronidation
helps to maintain the proper free thyroid
hormone levels. 
Indeed, synthetic chemicals can disrupt
nearly every step in the production and
metabolism of thyroid hormone (92,93)
(Table 1). Chemical interference with
uptake of iodide by the thyroid gland and,
more specifically with the sodium/iodide
symporter (which facilitates the iodide
uptake), can result in a decrease in the cir-
culating levels of T4/T3 (94,95). Chemical
exposure can also lead to a decrease in
serum protein–bound iodide levels, per-
haps largely due to inhibition of the thy-
roid peroxidase enzyme, which disrupts the
normal production of thyroid hormone
(96–98). The displacement of T4/T3 from
the transport proteins (TBG, transthyretin,
and albumin) may result in decreased abil-
ity of thyroid hormone to reach its target
tissue and may facilitate the transport of
the chemicals into the fetus (92,99).
Chemical disruption of the T4/T3 meta-
bolism can influence deiodinase, glu-
curonidase, and sulfatase activity, and may
ultimately result in increased biliary elimi-
nation of T4/T3. Inhibition of the deiodi-
nase enzymes can result in a decrease in T3
available to elicit thyroid action at the tis-
sue level (100). Conversely, deiodinase
activity may increase in response to chemi-
cal exposure, either as a direct effect or in
response to increased clearance of T4/T3 by
the chemical stimulation of glucuronidase
or sulfatase enzymes (101,102). Brucker-
Davis (93) suggests that such increases in
the metabolism and clearance of T3 could
result in a goiter as the thyroid gland
increases production to maintain proper
hormone levels. The list in Table 1 of 116
chemicals capable of disrupting normal thy-
roid hormone production, transport, and
metabolism is by no means exhaustive; fur-
ther discussion of the effects of disruption
of these processes can be found in reviews
by Brouwer et al. (92) and Brucker-Davis
(93). There are many more chemicals that
have effects on TSH and T4/T3 levels, and
thyroid histopathology for which no mech-
anism has been tested (93). It is unlikely
that these chemicals are working as T4/T3
agonists or antagonists at the level of TR
binding, as no chemical tested thus far has
demonstrated high affinity binding to the
mammalian TR. (103,104). 
Relatively few studies have evaluated
the mechanism of action of thyroid-dis-
rupting chemicals in the fetal/neonatal
organism. Darnerud et al. (105) reported
that developmental exposure to 4-OH-
3,5,3´,4´-tetrachlorobiphenyl, a major
metabolite of polychlorinated biphenyl
(PCB) congener 3,3´,4,4´-tetrachloro-
biphenyl (PCB 77), binds to fetal and
maternal transthyretin in mice on GD17;
significant decrease in fetal T4 (free and
total) was reported. Aminotriazole inhib-
ited the catabolism of T4 to T3 in renal pri-
mary cell cultures from 4 to 5 months of
gestation in human fetuses, indicating an
interference with type 1 iodothyronine
deiodinase function in the kidney (106).
In utero exposure to PCB congener
3,3´,4,4´,5,5´-hexachlorobiphenyl alone or
in combination with PCB 77 increased
type II deiodinase activity in whole-brain
homogenates from fetal (GD20) and
neonatal (PND7 and PND21) rats; total
T4 levels in plasma were decreased by both
treatments (107). UDP-GT activity was
increased in PND21 rat weanlings exposed
to the PCB congeners PCB 77, PCB 126
(3,3´,4,4´,5-pentachlorobiphenyl), or
TCDD (2,3,7,8-tetrachlorodibenzo-p-
dioxin) on GD10 (108). The increase in
UDP-GT activity was seen in the near
absence of significant decreases in T4 con-
centration on PND21 (108). Gestational
exposure to Aroclor 1254 depressed UDP-
GT activity in GD20 rat fetuses, while
increasing the enzyme in PND21 rats
(109). The total and free T4 levels in
GD20 fetuses were signiﬁcantly suppressed
by both levels of Aroclor 1254 exposure
during development, whereas the total T4
and total T3 were significantly depressed
on PND21 only by the highest dose of
Aroclor 1254 (109). The ability of man-
made chemicals to disrupt the thyroid sys-
tem strongly suggests the possibility of
chemical perturbation of thyroid-sensitive
brain development (92,110,111).
Chemical perturbation also influences
the interaction of the thyroid hormone and
RA systems. In young adult rats, RA is dis-
placed from its serum transport protein,
retinol binding protein, and the
transthyretin-retinol binding protein com-
plex by PCB 77 (112). Similar effects by
PCB 77 on binding to transport proteins
and serum levels of T4 have been reported
(99,105). Subchronic exposure to
2,2´,3,3´,4,4´-hexachlorobiphenyl
decreased kidney and liver levels of vitamin
A and significantly lowered frontal cortex
dopamine levels in rats dosed for 4 weeks
after weaning (113). Reduced follicle size
and papillary proliferation of the thyroid
epithelium were noted in all treatment lev-
els. Hallgren et al. (114) reported that
polybrominated diphenyl ether (PBDE)
and Bromokal (a PBDE mixture) given
orally to adult rats and mice significantly
depressed serum T4. Bromokal also
reduced vitamin A levels in the liver and
induced UDP-GT activity at the highest
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Table 1. Synthetic chemicals that interfere with the production, transport, and metabolism of thyroid hormone.
Thyroid mechanism and interfering chemical
Abbreviations: 2,4-D, 2,4-dichlorophenoxyacetic acid; DDD, 1,1-dichloro-2,2-bis(p-chlorophenyl) ethane.
Uptake of iodide by thyroid gland
2,4-D (137)
3-Amino-1,2,4-triazole (138,139)
Aldrin (140)
Amitrole (141,142)
Aroclor 1254 (143,145)
1,2-Dihydroxybenzene (catechol) (146)
4-Chlororesorcinol (146)
Clofentezine (141)
o-Cresol (146)
p-Cresol (146)
Cythion (96,147)
1,3-Dihydroxynaphthalene (146)
1,5-Dihydroxynaphthalene (146)
2,3-Dihydroxynaphthalene (146)
2,7-Dihydroxynaphthalene (146)
2,4-Dihydroxybenzaldehyde (146)
2,4-Dihydroxybenzoic acid (146)
Ethiozin (141)
Ethylene thiourea (141,148)
Fipronil (141)
Hexachlorobenzene (149,150)
Hexadrin (147)
4-Hexylresorcinol (146)
1,3,4-Trihydroxybenzene (hydroxyquinol) (146)
Hydroxyquinol triacetate (146)
Lead (151)
Mancozeb (152)
Mercuric chloride (153,154)
3-Methylcholanthrene (143,155)
Methylmercuric chloride (154)
Methylparathion (156)
2-Methylresorcinol (146)
Mull-Soy (157)
Nabam (140)
5-Methylresorcinol (orcinol) (146)
Pendimethalin (141)
Pentachloronitrobenzene (141)
Phenobarbital (143)
Phenol (146)
1,3,5-Trihydroxybenzene (phloroglucinol) (146)
Polybrominated biphenyls (158)
Pregnenolone-16α-carbonitrile (143)
Propylthiouracil (139,158)
1,2,3-Trihydroxybenzene (pyrogallol) (146)
Pyrimenthanil (141)
1,3-Dihyroxybenzene (resorcinol) (146)
o-Hydroxybenzyl alcohol (saligenin) (146)
Selenium (151)
Thiocyanate (141)
Sodium/iodide symporter
Perchlorate (94,159)
Perrhenate (159)
Serum protein–bound iodide level
2,4-D (137)
2,4-Dinitrophenol (96)
3-Methylcholanthrene (155)
Amitrole (142)
Aroclor 1254 (144)
Cythion (95,147)
Malathion (160)
Mancozeb (152)
Mercuric chloride (153)
o,p’-DDD (161,162)
Hexadrin (147)
Thyroid peroxidase action—general information
Amitrole (141)
Ammonia (163)
Ethylene thiourea (141)
Fipronil (141)
Mancozeb (141)
4,4’-Methylenedianiline (141)
Thiocyanate (141)
Thyroid peroxidase action—oxidation of iodide
Aminotriazole (97,164)
Ammonia (163)
Cadmium chloride (163,165)
Endosulfan (166)
Ethylene thiourea (98)
1,2,3,4,5,6-Hexachlorocyclohexane (lindane) (167)
Malathion (167)
Mancozeb (152)
Mercury chloride (165)
Methamizole (97)
Polybrominated biphenyls (158)
Thiourea (166)
Thyroid peroxidase action—iodination of tyrosine
Polybrominated biphenyls (158)
Binding to thyroglobulin
o,p´-DDD (161)
Pentachlorophenol (168)
Binding to transthyretin
Bromoxynil (3,5-bibromo-4-hydroxybenzonitril) (99)
4-(Chloro-o-tolyloxy) acetic acid (99)
4-(4-Chloro-2-methylphenoxy) butyric acid (99)
Chlorophenol (99,169)
Chloroxuron (99)
2,4-D (99)
2,4-Dichlorophenoxybutric acid (99)
Dioxtylphthalate (99)
o,p´-DDD (99)
p,p´-DDD (99)
2,3-Dichlorophenol (99,169)
2,4-Dichlorophenol (99)
2,6-Dichlorophenol (99,169,170)
2-(2,4-Dichlorophenoxy) propionic acid [dichloroprop] (99)
1,1,1-Trichloro-2,2-bis (chlorophenol) ethanol [difocol] (99)
2,4-Dinitrophenol (99)
2,4-Dinitro-6-methylphenol (99)
Ethyl-bromophos (99)
Ethyl-parathion (99)
2-(2,4,5-Trichlorophenoxy) propionic acid [fenoprop] (99)
Hexachlorobenzene (99)
Hexachlorophene (99,169)
2-Hydroxybiphenyl (99)
4-Hydroxybiphenyl (99,169)
Lindane (99)
Linuron (99)
Malathion (99)
Pentachlorophenol (99,169,170)
Phenol (169)
Pyrogallol (99)
2,4,5-Trichlorophenoxyacetic acid (99)
1,4-Tetrachlorophenol (99,170)
PCB-77 (99,105,169)
Trichloroacetic acid (99)
Trichlorobenzene (99)
2,3,4-Trichlorophenol (170)
2,4,5-Trichlorophenol (99,169,170)
2,4,6-Trichlorophenol (99,170)
2,4,5-Trichlorophenoxyacetic acid methyl ester (99)
Binding to albumin
Pentachlorophenol (169)
Catabolism of T4 or T3: type I or II 5´-deiodinase 
3,3´,4,4´,5,5´-Hexachlorobiphenyl (107)
3-Methylcholanthrene (171,172)
Aminotriazole (106)
Amiodarone (94,172)
Aroclor 1254 (109)
Cadmium chloride (173)
Diphenylthiohydantoin (141,172)
Dimethoate (100,174)
Fenvalerate (175,176)
Hexachlorobenzene (102)
Lead (177)
Phenobarbital (172)
Propylthiouracil (172)
PCB 77 (107,171)
TCDD (171,178)
Glucuronidation of T4/T3
Acetochlor (141)
Aroclor 1254 (109,143–145,179)
3,4-Benzpyrene (180)
Clofentenzine (141)
Cloﬁbrate (141)
DDT (144)
Fenbuconazole (141)
3,3´,4,4´,5,5´-Hexabromobiphenyl (101)
Hexachlorobenzene (102,183)
2,3,3´,4,4´,5-Hexachlorobiphenyl (182)
3,3´,4,4´,5,5´-Hexachlorobiphenyl (107)
3-Methylcholanthrene (141,143,155,171,179)
Pendimethalin (141)
PCB 126 (108,182)
Phenobarbital (141,143,172,180,181,183)
Polybrominated biphenyls (184)
PCBs (141)
Pregnenolone-16α-carbonitrile (141,143,179)
Promadiamine (141)
Pyrimethanil (141)
PCB 77 (108,171)
TCDD (108,141,178,182)
Thiazopyr (141)
Catabolism and biliary elimination of T4/T3
in the liver
Aroclor 1254 (144,145)
3,4-Benzopyrene (180)
DDT (144)
Hexachlorobenzene (102)
3-Methylcholanthrene (155)
Phenobarbital (180,183)
Polybrominated biphenyls (184)dose in the rats; similar results were found
for 2,3,3´,4,4´-pentachlorobiphenyl and
Aroclor 1254 (114). Further research is
needed to better understand how disrup-
tion of the vitamin A system may inﬂuence
the thyroid system and brain development. 
Thyroid Sensitivity of Nervous
System Derivatives
There are several nervous system deriva-
tives influenced by thyroid hormone.
Thyroid hormone receptor β2 isoform has
been identified in the outer nuclear layer
of the mouse retina, which contains the
developing photoreceptors (115) and is
thought to play a role in committing the
photoreceptor progenitor cells to becom-
ing green cone photoreceptor cells. The
pacemaker cells of the mammalian heart
contain TRα1 (42,116) and T3 may inﬂu-
ence pacemaker activity by increasing the
ion (Na+-Ca2+) activity (117). The follow-
ing section will discuss the thyroid-sensi-
tive nature of the development and
function of the cochlea. Impaired function
of the cochlea as well as of the eye and
heart have been reported in laboratory
studies as a result of thyroid perturbation
during development and could be useful
end points in detecting thyroid disruption.
Cochlear Development
Hearing loss is commonly associated with
thyroid disorders in humans, including
congenital hypothyroidism (118,119),
iodide deficiency (120), resistance to thy-
roid hormone (121), and Pendred syn-
drome (122). Likewise, deafness is reported
in the hyt/hyt mouse model with congeni-
tal hypothyroidism (123). TRβ1 and
TRβ2 mRNA are expressed in the rat fetus
as early as GD12.5 in the region of the otic
vesicle that gives rise to the cochlea (35).
Auditory function is mediated specifically
by TRβ, as evidenced by hearing loss in
mice lacking a functional TRβ, whereas
mice deﬁcient in TRα have normal hearing
(124,125). TRβ is necessary for develop-
ment of cochlear function; mice deficient
in TRβ exhibit delayed expression of a key
potassium conductance necessary for the
maturation of the cochlear inner hair cells
(125). Thyroid hormones acting through
TRβ also influence hearing by initiating
myelinogenesis of the cochlea and vestibu-
locochlear nerve (cranial nerve VIII) prior
to the onset of hearing (56). In rats, the
critical periods of thyroid-sensitive ear
development extend from at least GD18
(the onset of fetal thyroid gland function)
through PND18 (the period of outer hair
cell synaptogenesis in the cochlea)
(126–128). Brucker-Davis et al. (121) esti-
mate the critical period of thyroid-sensitive
cochlear development in humans extends
from the close of the ﬁrst trimester through
the ﬁrst month of life. 
Hypothyroidism caused by develop-
mental exposure to thyroid-disrupting
chemicals can also cause hearing loss. Adult
rats developmentally exposed to propylth-
iouracil (129), methimazole (130), or
Aroclor 1254 (131) have significantly ele-
vated auditory thresholds (i.e., less sensitive
hearing) relative to controls. Hearing
impairment caused by developmental expo-
sure to Aroclor 1254 was identified as
cochlear and/or auditory nerve dysfunction
(132). It was due, in part, to a decrease in
the abundance of outer hair cells in the
upper middle turn (responsible for detec-
tion of lower frequency sounds) as well as
the apical turn of the cochlea in rats (133).
In a subsequent experiment, postnatal
administration of T4 partially blocked low-
frequency hearing loss in rats developmen-
tally exposed to Aroclor 1254 (134). With
regard to human exposure, Chao et al.
(135) compared children in Yucheng,
Taiwan, who were born to women exposed
to PCB- and polychlorinated dibenzofu-
ran–contaminated rice oil with control
children whose mothers were not exposed.
Forty-four percent of children born to
exposed mothers had abnormal middle ear
morphology and/or impaired sound con-
ductance compared with 18.8% of the con-
trols. The identification of noninvasive
methods of detecting thyroid system dis-
ruption of nervous systems end points such
as impaired auditory thresholds may pro-
vide an important tool in laboratory and
epidemiologic studies.
Summary
By superimposing the development of the
thyroid system onto the chronology of
brain development, it is evident that thy-
roid hormone may influence brain struc-
ture and function during the earliest stages
of development in humans and rodents.
Further investigation is needed to better
understand the developmental patterns of
thyroid-sensitive genes as well as their
effects on brain development. Future ver-
sions of the timeline should also include
development of the brain beyond birth
and weaning, as many of the developmen-
tal processes continue well into adoles-
cence in humans (48). In addition, species
differences in the timing of brain develop-
ment should be considered in the identiﬁ-
cation of thyroid-sensitive brain processes
and developmental periods in mammals
(136) and other vertebrates. Most impor-
tant, as synthetic chemicals can interfere
with nearly every step in thyroid system
function, more research should be targeted
at understanding how thyroid-disruptive
chemicals may impact normal brain devel-
opment and functioning. By increasing the
knowledge of thyroid hormone influence
on brain development and how chemicals
can disrupt thyroid system function, scien-
tists can design more effective screens and
assays to test chemicals for their possible
impact on the thyroid system and down-
stream brain effects.
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